Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TPIV 200

Next Previous
Search
Drug Profile

TPIV 200

Alternative Names: Folate receptor alpha vaccine; Folate receptor alpha-loaded dendritic cell vaccine; FR alpha peptide vaccine; FRa peptide vaccine; FRalphaDC; HuFR-1; Multi-epitope folate receptor alpha peptide vaccine; TPIV200

Latest Information Update: 02 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Clinic
  • Developer Marker Therapeutics Inc; Mayo Clinic
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer; Triple negative breast cancer
  • No development reported Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 30 Nov 2022 No development reported - Phase-II for Triple-negative-breast-cancer (Monotherapy, Second-line therapy or greater) in USA (Intradermal)
  • 19 Jul 2021 Marker Therapeutics completes a phase II trial in Triple negative Breast cancer in USA (NCT02593227)
  • 20 Jan 2021 Marker Therapeutics in collaboration with MedImmune and Memorial Sloan Kettering Cancer Institute completes a phase II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in USA (Intradermal) (NCT02764333)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top